EytanMosheSteinMD

PubMed

• Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
  Pau Montesinos, Stéphane de Botton, Yue Zhu, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Amir T Fathi, Eytan M Stein, Amer M Zeidan, Thomas Prebet, Courtney D DiNardo> ;Blood Advances. 2024 Mar 20
• Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies.
  Krystel-Whittemore, M., Petrova-Drus, K., Ptashkin, R., Ewalt, M., Yao, J., Liu, Y., Zhu, M., Benhamida, J., Durham, B., Kumar, J., Nafa, K., Kiecka, I., Bowman, A., G...> ;Haematologica. 2024 Mar 7
• 1 citations
  Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
  Shai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Ev...> ;Leukemia. 2024 Apr 1
• Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
  Colak, G., Fusco, A., Mangan, J., Stein, E., Fathi, A., Harb, W.> ;Leukemia & Lymphoma. 2024 Apr 1
• 2 citations
  A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Cai, S., Huang, Y., Lance, J., Mao, H., Dunbar, A., McNulty, S., Druley, T., Li, Y., Baer, M., Stock, W., Kovacsovics, T., Blum, W., Schiller, G., Olin, R., Foran, J.,...> ;Blood Advances. 2024 Jan 23
• Traditional Medicare or Medicare Advantage? The Leukemia and Cancer Perspective.
  Rajkumar, V., Kantarjian, H., Zeidan, A., Fathi, A., Stein, E., Tefferi, A.> ;Mayo Clinic Proceedings. 2024 Jan 1
• Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
  Ryan N Ptashkin, Mark D Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova-Drus, Abhinita S Moh...> ;Nature Communications. 2023 Oct 28
• E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.
  Jan Philipp Bewersdorf, Justin Taylor, Xiaoli Mi, Namrata Sonia Chandhok, Justin Watts, Andriy Derkach, Mateusz Wysocki, Sydney X Lu, Jessie Bourcier, Simon J Hogg, Ja...> ;Leukemia. 2023 Dec 1
• Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
  Karthik Nath, Jasme Lee, Theresa A Elko, Lauren Levy, Elaina Preston, Sean M Devlin, Doris M Ponce, Richard J Lin, Brian C Shaffer, Christina Cho, Ioannis Politikos, A...> ;American Journal of Hematology. 2023 Dec 1
• 1 citations
  Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML withgene overexpression.
  Eytan M Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L Liesveld, Rachel J Cook, Philippe Rousselot, David A Rizzieri, Thorsten Braun, Gail J Roboz, ...> ;Leukemia & Lymphoma. 2023 Dec 1
• Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
  Uma Borate, Fei Yang, Richard Press, Amy S Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C Pavlick, Luke Juckett, Brianna Norris, Taylor Bu...> ;Blood Advances. 2023 Oct 24
• Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
  Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, Richard M Stone, Jessica K Altman, Amir T Fathi, Tharin Limsakun, Min Liang, Sung Choe, Mohammad Hossain, Adr...> ;American Journal of Hematology. 2023 Sep 1
• 5 citations
  Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.
  Joseph G W McCarter, David Nemirovsky, Christopher A Famulare, Noushin Farnoud, Abhinita S Mohanty, Zoe S Stone-Molloy, Jordan Chervin, Brian J Ball, Zachary D Epstein...> ;Blood Advances. 2023 Sep 12
• 15 citations
  Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
  Daniel A Pollyea, Jessica K Altman, Rita Assi, Dale Bixby, Amir T Fathi, James M Foran, Ivana Gojo, Aric C Hall, Brian A Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori...> ;Journal of the National Comprehensive Cancer Network. 2023 May 1
• 1 citations
  Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
  Vu H Duong, Amy S Ruppert, Alice S Mims, Uma Borate, Eytan M Stein, Maria R Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L Arellano, Gary J Schiller, Reb...> ;Cancer. 2023 Aug 1
• 65 citations
  The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
  Ghayas C Issa, Ibrahim Aldoss, John DiPersio, Branko Cuglievan, Richard Stone, Martha Arellano, Michael J Thirman, Manish R Patel, David S Dickens, Shalini Shenoy, Nee...> ;Nature. 2023 Mar 1
• 2 citations
  IDH2 inhibition in AML.
  Eytan M Stein> ;Blood. 2023 Jan 12
• 1 citations
  Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with-mutant acute myeloid leukemia.
  Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory M Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan> ;Leukemia & Lymphoma. 2023 Feb 1
• 12 citations
  Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
  Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J Cook, Philippe Rousselot, David A Rizzieri, Jane L Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Jose...> ;Blood Advances. 2023 May 9
• 3 citations
  Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
  Rose Parisi, Emily A Cowen, Joseph R Stoll, Haoling Zhu, Stephen Dusza, Melissa P Pulitzer, Eytan M Stein, Alina Markova> ;Leukemia Research. 2022 Dec 1
• 2 citations
  Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis.
  Shai Shimony, Alon Rozental, Jan P Bewersdorf, Aaron D Goldberg, Eytan M Stein, Alyssa A Grimshaw, Richard M Stone, Daniel J DeAngelo, Ofir Wolach, Maximilian Stahl> ;Haematologica. 2022 Dec 1
• Recent progress in acute leukemia and myelodysplasia.
  Hetty E Carraway, Daniel A Pollyea, Eytan M Stein> ;Best Practice & Research. Clinical Haematology. 2022 Dec 1
• 4 citations
  Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
  Antoine N Saliba, Scott H Kaufmann, Eytan M Stein, Prapti A Patel, Maria R Baer, Wendy Stock, Michael Deininger, William Blum, Gary J Schiller, Rebecca L Olin, Mark R ...> ;Blood Advances. 2023 Jun 13
• 3 citations
  Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
  Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo,...> ;Leukemia & Lymphoma. 2023 Jan 1
• 2 citations
  Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
  Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A ...> ;American Journal of Hematology. 2023 Jan 1
• Join now to see all

Journal Articles

• Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance  
  E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
• Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib  
  Eytan Stein, MD, Nature
• Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations  
  Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
• Abnormal Microarchitecture and Stiffness in Postmenopausal Women Using Chronic Inhaled Glucocorticoids  
  E Dimango, E Shane, E M Stein, Osteoporosis international
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML  
  Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
• Join now to see all

Abstracts/Posters

• RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propen...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
  Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid Disorders 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Adult Clinical Malignant Hematology 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Focus on AML: Clinical Practice Today 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute mye... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Enasidenib for Acute Myeloid Leukemia. FDA Approvals and Their Incorporation into Clinical Practice 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all